Loading
A phase 3 trial of Trastuzumab rezetecan, Pertuzumab, Docetaxel and Trastuzumab in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06057610 by Jiangsu HengRui Medicine Co., Ltd., with 868 participants enrolled, started 2023-11-01 and due to reach its primary completion in 2026-07-15. Interventions recorded: SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection and Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer and the tag pipeline.
Shares Trastuzumab rezetecan, Pertuzumab, Jiangsu Hengrui Pharmaceuticals, Trastuzumab and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/